Hijacking the bone niche: mechanistic insights into bone metastasis in breast cancer

Abstract

Breast cancer is one of the most common malignant tumors worldwide, with metastasis being the leading cause of mortality among patients. Bone is the most frequent site of metastasis in breast cancer, accounting for approximately 70% of metastatic cases. Before bone metastasis, primary breast cancer cells secrete circulating factors (e.g., exosomal RNAs, metabolites, and cytokines) to precondition the bone microenvironment and establish a supportive pre-metastatic niche (PMN). After dissemination, tumor cells further hijack the bone niche by releasing receptor activator of nuclear factor-κB ligand (RANKL), parathyroid hormone-related protein (PTHrP), and transforming growth factor-β (TGF-β), thereby disrupting bone homeostasis through osteoclast activation and osteoblast dysregulation. Bone matrix degradation subsequently releases latent growth factors that in turn fuel tumor cell proliferation, thereby establishing a self-reinforcing vicious cycle. Meanwhile, breast cancer cells actively induce local immunosuppression and promote angiogenesis, remodeling a pro-tumor bone niche conducive to metastatic outgrowth. This review highlights the immunosuppressive roles of immune cells and key molecular mediators in the vicious cycle, systematically analyzes intercellular crosstalk within both the bone PMN and the hijacked niche, and summarizes emerging therapeutic strategies (including novel targeted inhibitors, immune-based combinations, epigenetic modulation, and nanomedicines) beyond conventional treatments. These insights provide a theoretical framework and identify promising therapeutic targets for future treatment strategies against breast cancer bone metastasis.

References

[1] Xiong X, et al.. Breast cancer: pathogenesis and treatments. Signal Transduct. Target Ther., 2025, 10: 49.

[2] Giaquinto AN, et al.. Breast cancer statistics 2024. CA Cancer J. Clin., 2024, 74: 477-495

[3] Kennecke H, et al.. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol., 2010, 28: 3271-3277.

[4] Smid M, et al.. Subtypes of breast cancer show preferential site of relapse. Cancer Res., 2008, 68: 3108-3114.

[5] Nolan E, Kang Y, Malanchi I. Mechanisms of organ-specific metastasis of breast cancer. Cold Spring Harb. Perspect. Med, 2023, 13: a041326.

[6] Wu Q, et al.. SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches. Cell Res., 2023, 33: 464-478.

[7] Jiang WJ, et al.. Breast cancer subtype-specific organotropism is dictated by FOXF2-regulated metastatic dormancy and recovery. Cancer Res., 2025, 85: 644-659.

[8] Zhao C, et al.. NAT1 promotes osteolytic metastasis in luminal breast cancer by regulating the bone metastatic niche via NF-kappaB/IL-1B signaling pathway. Am. J. Cancer Res., 2020, 10: 2464-2479

[9] Hofbauer LC, et al.. Novel approaches to target the microenvironment of bone metastasis. Nat. Rev. Clin. Oncol., 2021, 18: 488-505.

[10] Croucher PI, Mcdonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. Nat. Rev. Cancer, 2016, 16: 373-386.

[11] Hadjidakis DJ, Androulakis. Ii. Bone remodeling. Ann. N. Y Acad. Sci., 2006, 1092: 385-396.

[12] Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res., 2010, 12. ArticleID: 215

[13] Sims NA, Martin TJ. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep., 2014, 3: 481.

[14] Fornetti J, Welm AL, Stewart SA. Understanding the bone in cancer metastasis. J. Bone Min. Res., 2018, 33: 2099-2113.

[15] Zaidi M. Skeletal remodeling in health and disease. Nat. Med., 2007, 13: 791-801.

[16] Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer, 2002, 2: 584-593.

[17] Kang Y, et al.. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3: 537-549.

[18] Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature, 2014, 507: 323-328.

[19] He F, et al.. Multiscale characterization of the mineral phase at skeletal sites of breast cancer metastasis. Proc. Natl. Acad. Sci. USA, 2017, 114: 10542-10547.

[20] Sun H, Huang W, Ji F, Pan Y, Yang L. Comparisons of metastatic patterns, survival outcomes and tumor immune microenvironment between young and non-young breast cancer patients. Front. Cell Dev. Biol., 2022, 10. ArticleID: 923371

[21] Hernandez RK, et al.. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer, 2018, 18. ArticleID: 44

[22] Demirkan B. The roles of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in breast cancer bone metastasis: potential targets for prevention and treatment. J. Clin. Med., 2013, 2: 264-282.

[23] Weilbaecher KN, Guise TA, Mccauley LK. Cancer to bone: a fatal attraction. Nat. Rev. Cancer, 2011, 11: 411-425.

[24] Ye J, et al.. Targeting hyperglycemic bone pre-metastatic niche for breast cancer bone metastasis therapy. Adv. Sci., 2025, 12. ArticleID: e04924

[25] Baldassarri I, et al.. An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche. Proc. Natl. Acad. Sci. USA, 2024, 121. ArticleID: e2405257121

[26] Wang X, et al.. Lymphotoxin-beta promotes breast cancer bone metastasis colonization and osteolytic outgrowth. Nat. Cell Biol., 2024, 26: 1597-1612.

[27] Kaplan RN, et al.. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 2005, 438: 820-827.

[28] Jackett KN, Browne AT, Aber ER, Clements M, Kaplan RN. How the bone microenvironment shapes the pre-metastatic niche and metastasis. Nat. Cancer, 2024, 5: 1800-1814.

[29] Hoshino A, et al.. Tumour exosome integrins determine organotropic metastasis. Nature, 2015, 527: 329-335.

[30] Wang L, et al.. Bone sialoprotein-alphavbeta3 integrin axis promotes breast cancer metastasis to the bone. Cancer Sci., 2019, 110: 3157-3172.

[31] Zhao L, Ma X, Yu J. Exosomes and organ-specific metastasis. Mol. Ther. Methods Clin. Dev., 2021, 22: 133-147.

[32] Morrissey SM, et al.. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab., 2021, 33: 2040-58.e10.

[33] Kim O, et al.. RAS‑stimulated release of exosomal miR‑494‑3p promotes the osteolytic bone metastasis of breast cancer cells. Int. J. Mol. Med, 2023, 52: 1-14.

[34] Yuan X, et al.. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics, 2021, 11: 1429-1445.

[35] Liu X, et al.. Tumor-derived exosomal lncRNA-MIR193BHG promotes bone metastasis of breast cancer by targeting the miR-489-3p/DNMT3A signaling axis in osteoclasts. J. Transl. Med., 2025, 23. ArticleID: 142

[36] Luo W, et al.. TGF-beta-driven EMT in cancer progression and drug resistance. Cytokine Growth Factor Rev., 2025, 85: 11-25.

[37] Xue W, et al.. Wnt/beta-catenin-driven EMT regulation in human cancers. Cell Mol. Life Sci., 2024, 81: 79.

[38] Barker HE, et al.. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res., 2011, 71: 1561-1572.

[39] Haj-Shomaly J, et al.. T cells promote metastasis by regulating extracellular matrix remodeling following chemotherapy. Cancer Res., 2022, 82: 278-291.

[40] Khalili-Tanha G, Radisky ES, Radisky DC, Shoari A. Matrix metalloproteinase-driven epithelial-mesenchymal transition: implications in health and disease. J. Transl. Med., 2025, 23. ArticleID: 436

[41] Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin. Cancer Biol., 2020, 60: 14-27.

[42] Ustach CV, et al.. A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res., 2010, 70: 9631-9640.

[43] Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res., 2005, 7: R788-R795.

[44] Jechlinger M, et al.. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Investig., 2006, 116: 1561-1570.

[45] Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol., 2006, 18: 516-523.

[46] Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev., 2003, 22: 337-358.

[47] Muller A, et al.. Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410: 50-56.

[48] Gennari A, et al.. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. Breast Cancer Res. Treat., 2020, 181: 61-68.

[49] Prasad D, et al.. Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort. Br. J. Cancer, 2024, 131: 1543-1554.

[50] Devignes CS, et al.. HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice. Proc. Natl. Acad. Sci. USA, 2018, 115: E992-E1001.

[51] Chen Q, Massague J. Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin. Cancer Res., 2012, 18: 5520-5525.

[52] Hiraga T, Ito S, Mizoguchi T. Opposing effects of granulocyte colony-stimulating factor on the initiation and progression of breast cancer bone metastases. Mol. Cancer Res., 2021, 19: 2110-2119.

[53] Karaplis AC, Goltzman D. PTH and PTHrP effects on the skeleton. Rev. Endocr. Metab. Disord., 2000, 1: 331-341.

[54] Kong YY, et al.. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 1999, 397: 315-323.

[55] Teitelbaum SL. Bone resorption by osteoclasts. Science, 2000, 289: 1504-1508.

[56] Suvannasankha A, Chirgwin JM. Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast Cancer Res., 2014, 16. ArticleID: 484

[57] Han Y, et al.. Tumors hijack macrophages for iron supply to promote bone metastasis and anemia. Cell, 2025, 188: 6335-54.e26.

[58] Katsuno Y, et al.. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene, 2008, 27: 6322-6333.

[59] Si W, Zhou J, Zhao Y, Zheng J, Cui L. SET7/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21. Cell Death Dis., 2020, 11. ArticleID: 151

[60] Li XQ, Lu JT, Tan CC, Wang QS, Feng YM. RUNX2 promotes breast cancer bone metastasis by increasing integrin alpha5-mediated colonization. Cancer Lett., 2016, 380: 78-86.

[61] Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell, 2011, 19: 192-205.

[62] Wang H, et al.. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell, 2015, 27: 193-210.

[63] Pathi SP, Lin DD, Dorvee JR, Estroff LA, Fischbach C. Hydroxyapatite nanoparticle-containing scaffolds for the study of breast cancer bone metastasis. Biomaterials, 2011, 32: 5112-5122.

[64] Hiraga T, Horibe K, Koide M, Yamashita T, Kobayashi Y. Sclerostin blockade promotes bone metastases of Wnt-responsive breast cancer cells. Cancer Sci., 2023, 114: 2460-2470.

[65] Finn RS. Targeting Src in breast cancer. Ann. Oncol., 2008, 19: 1379-1386.

[66] Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res., 2003, 92: 827-839.

[67] Reynaud C, et al.. Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Cancer Res., 2017, 77: 268-278.

[68] Di Mauro P, Croset M, Bouazza L, Clezardin P, Reynaud C. LOX, but not LOXL2, promotes bone metastasis formation and bone destruction in triple-negative breast cancer. J. Bone Oncol., 2024, 44. ArticleID: 100522

[69] Esposito M, Guise T, Kang Y. The biology of bone metastasis. Cold Spring Harb. Perspect Med., 2018, 8: a031252.

[70] Wu X, et al.. RANKL/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies. Front. Cell Dev. Biol., 2020, 8: 76.

[71] Corisdeo S, Gyda M, Zaidi M, Moonga BS, Troen BR. New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. Biochem. Biophys. Res. Commun., 2001, 285: 335-339.

[72] Dai R, et al.. Cathepsin K: the action in and beyond bone. Front. Cell Dev. Biol., 2020, 8: 433.

[73] Chavez-Macgregor M, et al.. Angiogenesis in the bone marrow of patients with breast cancer. Clin. Cancer Res., 2005, 11: 5396-5400.

[74] Bidwell BN, et al.. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med., 2012, 18: 1224-1231.

[75] Wang H, et al.. The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability. Cancer Cell, 2018, 34: 823-39.e7.

[76] Le Gall C, et al.. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res., 2007, 67: 9894-9902.

[77] Pratap J, et al.. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res., 2008, 68: 7795-7802.

[78] Li XQ, Zhang R, Lu H, Yue XM, Huang YF. Extracellular vesicle-packaged CDH11 and ITGA5 induce the premetastatic niche for bone colonization of breast cancer cells. Cancer Res., 2022, 82: 1560-1574.

[79] Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol., 1995, 146: 95-100

[80] Bellahcene A, Kroll M, Liebens F, Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J. Bone Min. Res., 1996, 11: 665-670.

[81] Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp. Oncol., 2004, 26: 179-184

[82] Yin JJ, et al.. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Investig., 1999, 103: 197-206.

[83] Yang K, et al.. IGF-1R mediates crosstalk between nasopharyngeal carcinoma cells and osteoclasts and promotes tumor bone metastasis. J. Exp. Clin. Cancer Res., 2024, 43: 46.

[84] Bartelt A, et al.. Lrp1 in osteoblasts controls osteoclast activity and protects against osteoporosis by limiting PDGF-RANKL signaling. Bone Res., 2018, 6: 4.

[85] Zabkiewicz C, Resaul J, Hargest R, Jiang WG, Ye L. Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance. Endocr. Relat. Cancer, 2017, 24: R349-R366.

[86] Kim B, et al.. A CTGF-RUNX2-RANKL axis in breast and prostate cancer cells promotes tumor progression in bone. J. Bone Min. Res., 2020, 35: 155-166.

[87] Lee C, et al.. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis. Cancer Lett., 2018, 414: 205-213.

[88] Sanchez C, Gabay O, Salvat C, Henrotin YE, Berenbaum F. Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthr. Cartil., 2009, 17: 473-481.

[89] Yang QK, Chen T, Wang SQ, Zhang XJ, Yao ZX. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. Angiogenesis, 2020, 23: 279-298.

[90] Thomas GP, Baker SU, Eisman JA, Gardiner EM. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J. Endocrinol., 2001, 170: 451-460.

[91] Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag. Res., 2011, 3: 177-189

[92] Mulcrone PL, et al.. Skeletal colonization by breast cancer cells is stimulated by an osteoblast and beta2AR-dependent neo-angiogenic switch. J. Bone Min. Res., 2017, 32: 1442-1454.

[93] Kawai T, et al.. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol., 2006, 169: 987-998.

[94] Pilard C, et al.. RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells. J. Immunother. Cancer, 2025, 13: e010753.

[95] Choi M, et al.. Inhibition of NF-kappaB by a TAT-NEMO-binding domain peptide accelerates constitutive apoptosis and abrogates LPS-delayed neutrophil apoptosis. Blood, 2003, 102: 2259-2267.

[96] Sato K, et al.. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med., 2006, 203: 2673-2682.

[97] Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl. Acad. Sci. USA, 2003, 100: 125-130.

[98] Yang M, Zhu L. Osteoimmunology: the crosstalk between T Cells, B Cells, and osteoclasts in rheumatoid arthritis. Int. J. Mol. Sci, 2024, 25: 2688.

[99] Takayanagi H, et al.. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature, 2000, 408: 600-605.

[100] Young N, Mikhalkevich N, Yan Y, Chen D, Zheng WP. Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma. J. Immunol., 2005, 175: 8287-8295.

[101] Wieder R. Awakening of dormant breast cancer cells in the bone marrow. Cancers, 2023, 15: 3021.

[102] Duong HQ, Kafer G, Maugham-Macan M. Bone metastasis in endocrine-related cancer: unravelling invasion and destruction. Endocr. Relat. Cancer, 2025, 32: e240294

[103] Monteiro AC, et al.. Cooperation between T and B cells reinforce the establishment of bone metastases in a mouse model of breast cancer. Bone, 2024, 178. ArticleID: 116932

[104] Monteiro AC, Bonomo A. Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption. Bone, 2021, 143. ArticleID: 115755

[105] Liu W, et al.. Characterizing the tumor microenvironment at the single-cell level reveals a novel immune evasion mechanism in osteosarcoma. Bone Res., 2023, 11: 4.

[106] Arellano DL, et al.. Bone microenvironment-suppressed T cells increase osteoclast formation and osteolytic bone metastases in mice. J. Bone Min. Res., 2022, 37: 1446-1463.

[107] Cheng JN, et al.. Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. Cancer Cell., 2025, 43: 1093-107.e9.

[108] Liu C, et al.. Immune checkpoint inhibitor therapy for bone metastases: specific microenvironment and current situation. J. Immunol. Res., 2021, 2021. ArticleID: 8970173

[109] Maeda K, et al.. The regulation of bone metabolism and disorders by Wnt signaling. Int. J. Mol. Sci., 2019, 20: 5525.

[110] Breuer EK, et al.. Potassium channel activity controls breast cancer metastasis by affecting beta-catenin signaling. Cell Death Dis., 2019, 10. ArticleID: 180

[111] Satriyo PB, et al.. Cadherin 11 inhibition downregulates beta-catenin, deactivates the canonical WNT signalling pathway and suppresses the cancer stem cell-like phenotype of triple negative breast cancer. J. Clin. Med., 2019, 8: 148.

[112] Xi Y, Chen Y. Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis. Cancer Lett., 2014, 353: 8-16.

[113] Niida A, et al.. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene, 2004, 23: 8520-8526.

[114] Eyre R, et al.. Microenvironmental IL1beta promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nat. Commun., 2019, 10. ArticleID: 5016

[115] Evenepoel P, D’haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int., 2015, 88: 235-240.

[116] Zhuang X, et al.. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat. Cell Biol., 2017, 19: 1274-1285.

[117] Paic F, et al.. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone, 2009, 45: 682-692.

[118] Venetis K, et al.. Breast cancer with bone metastasis: molecular insights and clinical management. Cells, 2021, 10: 1377.

[119] Bao Q, et al.. The dual roles of circular RNAs in breast cancer distant metastasis and their clinical applications. J. Cancer, 2025, 16: 3270-3282.

[120] Xu Y, et al.. CircMMP2(6,7) cooperates with beta-Catenin and PRMT5 to disrupt bone homeostasis and promote breast cancer bone metastasis. Cancer Res., 2024, 84: 328-343.

[121] Xu Y, et al.. Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-kappaB/bone remodeling factors signaling. Mol. Cancer, 2021, 20. ArticleID: 98

[122] Long T, Tan M. To investigate the role and potential mechanism of has_circ_RBMS3 in bone metastasis of breast cancer based on bioinformatics. Cell Biochem. Biophys., 2024, 82: 2227-2236.

[123] Wang Z, et al.. miRNA interplay: mechanisms and therapeutic interventions in cancer. MedComm–Oncol., 2024, 3. ArticleID: e93

[124] Liu S, et al.. ceRNA network development and tumour-infiltrating immune cell analysis of metastatic breast cancer to bone. J. Bone Oncol., 2020, 24. ArticleID: 100304

[125] Sun Z, et al.. LncRNA SNHG3 regulates the BMSC osteogenic differentiation in bone metastasis of breast cancer by modulating the miR-1273g-3p/BMP3 axis. Biochem. Biophys. Res. Commun., 2022, 594: 117-123.

[126] Zhu J, et al.. LncRNA TRG-AS1 inhibits bone metastasis of breast cancer by the miR-877-5p/WISP2 axis. Pathol. Res Pract., 2023, 243. ArticleID: 154360

[127] Zhao Y, et al.. Long noncoding RNA Malat1 protects against osteoporosis and bone metastasis. Nat. Commun., 2024, 15. ArticleID: 2384

[128] Barwal TS, et al.. MicroRNAs and long noncoding RNAs as novel therapeutic targets in estrogen receptor-positive breast and ovarian cancers. Int. J. Mol. Sci., 2021, 22: 4072.

[129] Zou Y, et al.. Clinical approaches to overcome PARP inhibitor resistance. Mol. Cancer, 2025, 24. ArticleID: 156

[130] Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. J. Clin. Investig., 2017, 127: 761-771.

[131] Croset M, et al.. TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J. Bone Min. Res., 2014, 29: 1886-1899.

[132] Liu J, et al.. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer. Sci. Rep., 2017, 7. ArticleID: 40487

[133] Balkrishna A, Mittal R, Bishayee A, Kumar AP, Bishayee A. miRNA signatures affecting the survival outcome in distant metastasis of triple-negative breast cancer. Biochem. Pharm., 2025, 231. ArticleID: 116683

[134] Cai WL, et al.. microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. Mol. Cancer, 2018, 17. ArticleID: 9

[135] Taipaleenmaki H, et al.. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res., 2015, 75: 1433-1444.

[136] Croset M, et al.. miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res., 2018, 78: 5259-5273.

[137] Adams BD, et al.. miR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer. Cancer Res., 2016, 76: 927-939.

[138] Zhang X, et al.. MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9. Bone, 2020, 130. ArticleID: 115139

[139] Lv F, Qin J, Kong S, Pan L, Ding R. MicroRNA-506 ameliorates breast cancer-induced osteolytic bone metastasis via the NFATc-1 signaling pathway. J. Biochem. Mol. Toxicol., 2022, 36. ArticleID: e23156

[140] Law YY, et al.. Ugonin P mitigates osteolytic bone metastasis by suppressing MDK via upregulating miR-223-3p expression. Int. J. Biol. Sci., 2025, 21: 3740-3754.

[141] Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 2007, 449: 682-688.

[142] Puppo M, Valluru MK, Clezardin P. MicroRNAs and their roles in breast cancer bone metastasis. Curr. Osteoporos. Rep., 2021, 19: 256-263.

[143] Lipton A. Bone continuum of cancer. Am. J. Clin. Oncol., 2010, 33: S1-S7.

[144] Biermann JS, et al.. Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J. Natl. Compr. Canc. Netw., 2025, 23: e250017.

[145] Cardoso F, et al.. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol., 2020, 31: 1623-1649.

[146] Liu Y, et al.. Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: a subgroup analysis of a randomized, double-blinded phase III study. Chin. J. Cancer Res., 2025, 37: 337-351.

[147] Kobayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. Osteoporos. Int., 2024, 35: 1377-1393.

[148] Coleman R, et al.. Bone health in cancer: ESMO clinical practice guidelines. Ann. Oncol., 2020, 31: 1650-1663.

[149] Fizazi K, et al.. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 2011, 377: 813-822.

[150] Gradishar WJ, et al.. Breast Cancer, Version 3.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw., 2024, 22: 331-357.

[151] Gnant M. Role of bisphosphonates in postmenopausal women with breast cancer. Cancer Treat. Rev., 2014, 40: 476-484.

[152] Wilson C, et al.. Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. Eur. J. Cancer, 2018, 94: 70-78.

[153] Coleman R, et al.. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol., 2014, 15: 997-1006.

[154] Mi L, et al.. Expanding the Horizon of MRONJ research in breast cancer bone metastasis treatments. J. Clin. Oncol., 2025, 43: 1168-1169.

[155] Yang G, et al.. Medication-related osteonecrosis of the jaw in cancer patients: result from the oneflorida clinical research consortium. J. Bone Min. Res., 2022, 37: 2466-2471.

[156] Brunner C, et al.. Incidence of medication-related osteonecrosis of the jaw in patients with breast cancer during a 20-year follow-up: a population-based multicenter retrospective study. J. Clin. Oncol., 2025, 43: 180-188.

[157] Tenore G, et al.. Does medication-related osteonecrosis of the jaw influence the quality of life of cancer patients?. Biomedicines, 2020, 8: 95.

[158] Kubeczko M, et al.. Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors. Radiother. Oncol., 2025, 202. ArticleID: 110639

[159] Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist’s perspective. Urology, 2015, 85: 717-724.

[160] Deshayes E, et al.. Radium 223 dichloride for prostate cancer treatment. Drug Des. Devel Ther., 2017, 11: 2643-2651.

[161] Rugo HS, et al.. Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. Breast Cancer Res. Treat., 2024, 204: 249-259.

[162] Wu A, et al.. Trametinib boosts palbociclib’s efficacy in breast cancer via autophagy inhibition. Oncol. Res., 2024, 32: 1197-1207.

[163] Regua AT, et al.. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers. Cancer Lett., 2024, 597. ArticleID: 217023

[164] Zou Y, et al.. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resist. Updat, 2024, 77. ArticleID: 101126

[165] Mcdonald MM, et al.. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell, 2021, 184: 1330-47.e13.

[166] Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med., 2005, 83: 170-179.

[167] Zheng J, et al.. Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction. J. Adv. Res., 2025, 69: 399-411.

[168] Zheng H, et al.. Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy. Cancer Cell, 2017, 32: 731-47.e6.

[169] Duong LT, Wesolowski GA, Leung P, Oballa R, Pickarski M. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis. Mol. Cancer Ther., 2014, 13: 2898-2909.

[170] Oswald AJ, et al.. Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Res. Treat., 2023, 199: 35-46.

[171] Yang L, et al.. Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer. Cell Death Differ., 2020, 27: 2066-2080.

[172] Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell, 2019, 24: 65-78.

[173] Zhang J, et al.. PRMT1-mediated PARP1 methylation drives lung metastasis and chemoresistance via p65 activation in triple-negative breast cancer. Research, 2025, 8. ArticleID: 0854

[174] Wang S, et al.. YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation. Cancer Lett., 2024, 597. ArticleID: 217047

[175] Bado IL, et al.. The bone microenvironment increases phenotypic plasticity of ER(+) breast cancer cells. Dev. Cell, 2021, 56: 1100-1117.e9.

[176] Fan D, et al.. Phosphate ion-responsive and calcium peroxide-based nanomedicine for bone-targeted treatment of breast cancer bone metastasis. Adv. Health. Mater., 2024, 13. ArticleID: e2402216

[177] Gao H, et al.. Dual ligand-targeted Pluronic P123 polymeric micelles enhance the therapeutic effect of breast cancer with bone metastases. Oncol. Res., 2024, 32: 769-784.

[178] Winnard PTJr, et al.. Targeting RNA helicase DDX3X with a small molecule inhibitor for breast cancer bone metastasis treatment. Cancer Lett., 2024, 604. ArticleID: 217260

[179] Zou Y, Zhang H, Liu F, Chen ZS, Tang H. Intratumoral microbiota in orchestrating cancer immunotherapy response. J. Transl. Int. Med, 2024, 12: 540-542.

[180] Yue Z, et al.. RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis. J. Clin. Investig., 2022, 132: e144579.

[181] Tian Z, et al.. Bone-specific enhancement of antibody therapy for breast cancer metastasis to bone. ACS Cent. Sci., 2022, 8: 312-321.

[182] Ganesan K, et al.. Ononin inhibits tumor bone metastasis and osteoclastogenesis by targeting mitogen-activated protein kinase pathway in breast cancer. Resrarch, 2024, 7: 0553

Funding

Guangzhou Science and Technology Program key projects(2023A04J1785)

RIGHTS & PERMISSIONS

The Author(s)